Novartis, Sun Pharma settle dispute over generic Gleevec

ZURICH/MUMBAI Thu May 15, 2014 1:24pm IST

A Novartis logo is pictured on its headquarters building in Mumbai February 6, 2014. REUTERS/Danish Siddiqui/Files

A Novartis logo is pictured on its headquarters building in Mumbai February 6, 2014.

Credit: Reuters/Danish Siddiqui/Files

Related Topics

Stocks

   
Rajalakshmi (C), 28, smiles after winning the Miss Wheelchair India beauty pageant in Mumbai November 26, 2014. REUTERS/Danish Siddiqui

Miss Wheelchair India

Seven women from across India participated in the country's second wheelchair beauty pageant, which aims to open doors for the wheelchair-bound in modelling, film and television, according to organisers  Slideshow 

ZURICH/MUMBAI (Reuters) - Novartis (NOVN.VX) won a seven-month reprieve from generic competition to its blockbuster leukemia drug Gleevec after reaching a settlement on Thursday with Sun Pharmaceutical Industries Ltd(SUN.NS).

Competition from copycat drugs is a major worry for the Basel-based drugmaker, which unveiled a series of deals worth over $25 billion aimed at strengthening its cancer business and exiting underperforming operations last month.

Novartis is looking to plug the hole left by the upcoming expiration of its patent for Gleevec with other treatments, as well as stave off generic competition to the lucrative drug for as long as possible.

Sun, which has tentative approval from the U.S. Food and Drug Administration for a generic version of Gleevec, is the most tangible threat to Novartis' drug.

The drugmaker missed first-quarter sales forecasts last month, blaming a slowdown in sales of the leukemia drug as well as generic competition for Zometa, a bone repair drug.

Under the settlement with Sun, that firm will be allowed to launch a generic version of Gleevec in the United States on Feb. 1, 2016, which gives Novartis seven extra months without the competition from the Indian firm.

"This settlement validates the Novartis patents while allowing Sun Pharma's subsidiary to enter the market with its generic product," Novartis said.

The settlement is mildly positive for Novartis, according to analysts, although investors may have been hoping for a longer delay to Sun's product reaching the market.

"Whilst this settlement might not be as long a delay as some might have hoped for, it nonetheless should provide upside to current expectations," Jefferies analyst Jeffrey Holford said in a note to investors.

Novartis shares traded 0.2 percent lower at 79.90 Swiss francs following the ruling, compared to a 0.3 percent rise in a European index of drug stocks.

(Reporting by Katharina Bart and Aradhana Aravindan; editing by Anupama Dwivedi and Tom Pfeiffer)

FILED UNDER:

REUTERS SHOWCASE

WTO Trade Deal

WTO Trade Deal

WTO clinches first global trade deal in its history  Full Article 

Kashmir Attack

Kashmir Attack

Ten dead in Kashmir's worst militant attack in more than a year  Read 

OPEC Meeting

OPEC Meeting

Saudis block OPEC output cut, oil price sinks further.  Full Article 

E-Commerce Boom

E-Commerce Boom

Online grocers come up trumps in India's e-commerce boom   Full Article 

GDP, RBI Preview

GDP, RBI Preview

GDP growth set to weaken, business wants reforms more than rate cut  Full Article | Related Story 

Jaitley to Rajan

Jaitley to Rajan

Jaitley likely to meet Rajan on Monday to urge rate cut  Full Article 

Banking Sector

Banking Sector

India moves to allow more businesses to offer basic financial services.  Full Article 

Jamini Roy

Jamini Roy

Photo Gallery – Bengali household name Jamini Roy’s paintings  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage